| scholarly article | Q13442814 |
| P50 | author | Barbara Picconi | Q42663948 |
| Ted M. Dawson | Q56046960 | ||
| P2093 | author name string | Valina L Dawson | |
| Yingfei Wang | |||
| Paolo Calabresi | |||
| Jeannette N Stankowski | |||
| Massimiliano Di Filippo | |||
| Antongiulio Gallina | |||
| P2860 | cites work | Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 |
| The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease | Q24339515 | ||
| Neuroprotection by pharmacologic blockade of the GAPDH death cascade | Q24545207 | ||
| Adenosine A2A receptors and basal ganglia physiology | Q24669783 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications | Q28247343 | ||
| Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients | Q28477288 | ||
| Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice | Q28507051 | ||
| A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia | Q28569068 | ||
| Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation | Q28582177 | ||
| Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos) | Q28589281 | ||
| Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms | Q28595038 | ||
| Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease | Q29346490 | ||
| Ageing and Parkinson's disease: substantia nigra regional selectivity | Q29615835 | ||
| Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor | Q29619105 | ||
| FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity | Q30491749 | ||
| Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys | Q30498354 | ||
| Synaptic plasticity in the ischaemic brain | Q30880841 | ||
| Evidence of a breakdown of corticostriatal connections in Parkinson's disease. | Q33214147 | ||
| NR2B subunit exerts a critical role in postischemic synaptic plasticity | Q33245460 | ||
| Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? | Q33890256 | ||
| Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. | Q33927861 | ||
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models | Q33964804 | ||
| Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. | Q34100460 | ||
| Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
| Dopamine-dependent synaptic plasticity in striatum during in vivo development | Q34658296 | ||
| TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid | Q34660982 | ||
| Pathologically activated therapeutics for neuroprotection | Q34691239 | ||
| Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease | Q35176103 | ||
| Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage | Q35180889 | ||
| LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice | Q35288337 | ||
| Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. | Q35607243 | ||
| Parthanatos, a messenger of death | Q35670138 | ||
| Poly(ADP-ribose) (PAR) polymer is a death signal | Q35722332 | ||
| Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough | Q35751844 | ||
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
| Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells | Q35793059 | ||
| Deadly conversations: nuclear-mitochondrial cross-talk | Q35891836 | ||
| Striatal synaptic plasticity: implications for motor learning and Parkinson's disease | Q36047483 | ||
| Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease | Q36057484 | ||
| Role of nitric oxide on motor behavior | Q36209135 | ||
| The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease | Q36325701 | ||
| Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism | Q36369850 | ||
| Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. | Q36611489 | ||
| Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease | Q36734840 | ||
| Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 | ||
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
| Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease | Q36821186 | ||
| Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease | Q36899588 | ||
| Plasticity and repair in the post-ischemic brain. | Q37116441 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| Invited Article: Nervous system pathology in sporadic Parkinson disease | Q37161890 | ||
| Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. | Q37313530 | ||
| Why have we failed to achieve neuroprotection in Parkinson's disease? | Q37363916 | ||
| Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos | Q37426834 | ||
| Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. | Q37580467 | ||
| Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Q37680104 | ||
| Synaptic dysfunction in Parkinson's disease. | Q37713858 | ||
| Complex I: inhibitors, inhibition and neurodegeneration | Q37723579 | ||
| Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease | Q37778900 | ||
| Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. | Q37794467 | ||
| Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. | Q37868192 | ||
| An update on adenosine A2A receptors as drug target in Parkinson's disease | Q37916633 | ||
| Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. | Q39801798 | ||
| Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. | Q40355180 | ||
| Molecular and biochemical features of poly (ADP-ribose) metabolism | Q40776253 | ||
| Striatal interneurones: chemical, physiological and morphological characterization | Q40991491 | ||
| Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia | Q41624006 | ||
| A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. | Q42453237 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? | Q42785592 | ||
| Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. | Q42852538 | ||
| Neuroscience: Brain's traffic lights | Q42961768 | ||
| Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death | Q43095369 | ||
| Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons | Q43120316 | ||
| Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions | Q44193907 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector | Q44661842 | ||
| Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. | Q44842409 | ||
| Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. | Q44931344 | ||
| Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons | Q45299250 | ||
| Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. | Q46005646 | ||
| Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. | Q46418668 | ||
| Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. | Q46896175 | ||
| Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission | Q46986845 | ||
| Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. | Q48114419 | ||
| Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. | Q48194148 | ||
| A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. | Q48257417 | ||
| Nitric oxide in neurodegeneration | Q48290890 | ||
| Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome | Q48437608 | ||
| Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. | Q48847188 | ||
| Long-term Potentiation in the Striatum is Unmasked by Removing the Voltage-dependent Magnesium Block of NMDA Receptor Channels. | Q52079554 | ||
| Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. | Q54569462 | ||
| The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease | Q60715991 | ||
| NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen | Q71687246 | ||
| Unilateral dopamine denervation blocks corticostriatal LTP | Q73280384 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 51-60 | |
| P577 | publication date | 2012-08-23 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | New synaptic and molecular targets for neuroprotection in Parkinson's disease | |
| P478 | volume | 28 |
| Q37232753 | Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons |
| Q39122432 | Decoding the substrate supply to human neuronal nitric oxide synthase. |
| Q35716460 | Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models |
| Q35307838 | Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways. |
| Q27002626 | Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? |
| Q104509587 | Maternal stress programs accelerated aging of the basal ganglia motor system in offspring |
| Q30367059 | Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound |
| Q39647087 | PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity |
| Q36164724 | Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options |
| Q28394979 | Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition |
| Q39113288 | Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. |
| Q92918998 | The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients |
| Q44513107 | The vatican meeting on neuroprotection for Parkinson's disease |
Search more.